Today's Advertiser Page 60 "Stocks ripe for the picking 2020
ASX PAR. We are picking Paradigm for a third year in a row. after rising 275% in 2018 and 184% year to December 2017 The company continues to develop injectable Pentosan Polysulphate Sodium IPPS for treatment of osteoarthritis, a market measured in the billions of dollars.
key progress we expect this year includes beginning US Food and Drug Administration approved phase 3 trials. Due to the large numbers of people treated with IPPS under the Special Access Scheme in Australia, we expect rapid sales growth once approved!
The word is definitely spreading IMO
research reports and media, page-421
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 22.0¢ | $93.40K | 419.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 23885 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 300 | 2 |
View Market Depth
| Last trade - 11.28am 20/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |